Acrivon Therapeutics Net Debt Growth & History (ACRV)
Acrivon Therapeutics's net debt was −$38.8M for fiscal 2025.
View full Acrivon Therapeutics company overviewAcrivon Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$38.8M | −$2.6M | — |
| 2024 | 2024-12-31 | −$36.2M | −$4.8M | — |
| 2023 | 2023-12-31 | −$31.4M | −$6.8M | — |
| 2022 | 2022-12-31 | −$24.6M | $69.4M | — |
| 2021 | 2021-12-31 | −$94.0M | — | — |
Acrivon Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$39.3M | −$670,000 | — |
| Q1 2026 | 2026-03-31 | −$31.6M | $4.0M | — |
| Q4 2025 | 2025-12-31 | −$38.8M | −$2.6M | — |
| Q3 2025 | 2025-09-30 | −$32.4M | $7.0M | — |
| Q2 2025 | 2025-06-30 | −$38.6M | $3.2M | — |
| Q1 2025 | 2025-03-31 | −$35.6M | −$15.5M | — |
| Q4 2024 | 2024-12-31 | −$36.2M | −$4.8M | — |
| Q3 2024 | 2024-09-30 | −$39.4M | −$14.0M | — |
| Q2 2024 | 2024-06-30 | −$41.8M | −$8.3M | — |
| Q1 2024 | 2024-03-31 | −$20.2M | $2.5M | — |
| Q4 2023 | 2023-12-31 | −$31.4M | −$6.8M | — |
| Q3 2023 | 2023-09-30 | −$25.4M | $1.5M | — |
| Q2 2023 | 2023-06-30 | −$33.5M | — | — |
| Q1 2023 | 2023-03-31 | −$22.7M | — | — |
| Q4 2022 | 2022-12-31 | −$24.6M | $69.4M | — |
| Q3 2022 | 2022-09-30 | −$26.9M | — | — |
| Q4 2021 | 2021-12-31 | −$94.0M | — | — |
Acrivon Therapeutics net debt trends
Between the periods ended 2021-12-31 and 2025-12-31, Acrivon Therapeutics's net debt increased from −$94.0M to −$38.8M, a change of $55.2M. The latest reported quarter, Q2 2026, shows −$39.3M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acrivon Therapeutics source filings ↗